NEW YORK (GenomeWeb) – The Centre for Drug Research and Development (CDRD), a Canadian national drug development and commercialization center, said today that it has spun out a company, Sepset Biosciences, that's developing a rapid diagnostic blood test with an objective to provide early, targeted treatment for sepsis.

The blood test, which is founded on work led by University of British Columbia researcher Robert Hancock, detects a unique biomarker signature based on the body's immune response, rather than the presence of a pathogen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.